VuMedi raises $104M Series B to scale AI physician learning tools
What's the deal? VuMedi, a peer-to-peer learning community for physicians, has expanded its AI-powered learning tools following a $104 million Series B investment from Oak HC/FTDealroom has a profile for this one. Try Dealroom →. The capital has funded hiring, research and development, product work, and outreach.
What's the endgame? VuMedi's AI turns more than 100,000 physician-led videos and nearly 5,000 podcast episodes across more than 21 specialties into an on-demand resource. Doctors ask a clinical question, and the system surfaces relevant specialist perspectives, then lets them jump to the time-stamped moment in the source video to see procedural technique and treatment sequencing.
Why now? The company cited research showing the time for a treatment to reach peak adoption has grown from roughly two to three years to six to seven years. That gap has clinical and commercial implications for doctors, drugmakers, and device companies trying to keep pace with new evidence.
The round sits in the top 7% by size among all US Series B rounds in healthcare, per funding data covering 3,704 comparable deals.
Since launching less than a year ago, VuMedi's AI tools have been used by more than 150,000 NPI-verified clinicians, generating more than 1 million interactions. Those users spend 3.5 times more time on the platform and watch 122% more video than non-AI users. Physicians now log more than 4.3 million minutes a month on the platform.
VuMedi positions itself against tools that mainly retrieve or summarise published literature. "Some of the most valuable knowledge in medicine lives in how experienced physicians actually practice," said Roman Giverts, founder and chief executive officer of VuMedi.
Investor Andrew Adams, co-founder and managing partner of Oak HC/FT, tied the deal to demand for clear clinical education. "Vumedi is even better positioned to deliver greater value to the healthcare community," he said. Oak HC/FT manages more than $10 billion in assets across over 120 portfolio companies.
What could go wrong? VuMedi's engagement figures are self-reported, so they show early usage rather than proven clinical impact or commercial returns. Grounding AI answers in a closed library of peer content may limit coverage as evidence and treatments proliferate.
The signal: The round reflects a broader shift in physician education toward AI-enabled, on-demand access to clinical information — Medscape launched its own AI assistant in late 2025. VuMedi's bet is that peer experience, not a generic chatbot, is the harder asset to replicate.
Read more: itbrief.news, businesswire.com
Image credit: VuMedi
